

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2021

ZIVO BIOSCIENCE, INC.

(Exact name of Registrant as Specified in Its Charter)

<u>Nevada</u> (State or Other Jurisdiction of Incorporation)	<u>000-30415</u> (Commission File Number)	<u>87-0699977</u> (IRS Employer Identification No.)
<u>2804 Orchard Lake Road, Suite 202, Keego Harbor Michigan</u> (Address of Principal Executive Offices)		<u>48320</u> (Zip Code)

Registrant's Telephone Number, Including Area Code: (248) 452-9866

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
<u>Common Stock, par value \$0.001 per share</u>	<u>ZIVO</u>	<u>The Nasdaq Stock Market</u>
<u>Warrants to purchase shares of Common Stock, par value \$0.001 per share</u>	<u>ZIVOW</u>	<u>The Nasdaq Stock Market</u>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Zivo Bioscience, Inc. will deliver a presentation at its Annual Meeting of Shareholders on October 12, 2021. The presentation will include the information in the slides furnished with this Current Report on Form 8-K as Exhibit 99.1

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Annual Meeting Presentation
104	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIVO BIOSCIENCE, INC.

Dated: October 12, 2021

By: /s/ Keith Marchiando
Keith Marchiando
Chief Financial Officer, Secretary and Treasurer



ZIVO Bioscience, Inc.

Annual Shareholders Meeting

Detroit, Michigan

October 2021

Transformative Opportunities in Immune Health & Nutrition



Notice

Safe Harbor Statement

Except for any historical information, the matters discussed in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.



2021 Annual Shareholder Meeting

October 12, 2021

WELCOME

Meeting Open

CFO REPORT

Keith R. Marchiando
Chief Financial Officer



2021 Annual Shareholders Meeting

October 12, 2021

CEO Report to Shareholders

Andrew A. Dahl
President & Chief Executive Officer



ZIVO Bioscience, Inc.
A new path to optimal health

**We are creating novel
drug candidates and
functional food
ingredients designed to
boost immune health in
humans and animals**

ZIVO BIOSCIENCE, INC.
NASDAQ: ZIVO; ZIVOW



2020 Annual Shareholders Meeting


Notice to Shareholders and Investors

This presentation and any Exhibits to it contain forward-looking statements that involve risks and uncertainties. These statements reflect the Company's future plans, objectives, expectations and intentions, and the assumptions underlying or relating to any of these statements. These statements may be identified by the use of the words "anticipate," "expect," "estimate," "intend," "believe," and similar expressions. The Company's actual results could differ materially from those discussed in these statements. Factors that could contribute to these differences include, but are not limited to, those discussed in this document.





2021 – The Watershed Year



Strongest Position Ever

- Capital funding completed
 - Robust intellectual property portfolio
 - Commercial initiatives underway
 - Pursuing licensing and joint development deals
 - Resources to pursue such opportunities
-



Public Offering and Up-Listing to Nasdaq Exchange



Biotech

Biotechnology

y

Molecules
Compounds
Complexes

AgTech

Agricultural Technology

Algal Biomass
Extracts
Dry Mixes



Summary of Events

- June 2, 2021 registered public offering underwritten by Maxim Group
 - Gross proceeds of \$13.8M
 - Net proceeds of \$12.2M
 - Underwriter's partial exercise nets \$740K
 - S-3 shelf registration completed
-



Production, Validation and New Applications



Biotech
Biotechnology
y

Molecules
Compounds
Complexes



Manufacturing Development & Feasibility

- Development work for fermentation processes concluded 2021
 - Production ramped to 1,000L reactors to establish costing parameters for licensees
 - Purification and optimization in process to determine feasibility for refined bioproducts and biopharmaceuticals with potentially higher margins
 - Synthetic candidate to be included in next round of validation studies
-



Poultry Product Validation & Licensing



Biotech
Biotechnology
y

Molecules
Compounds
Complexes



Discovery Stage Licensing Candidate

- Study #18 validates significantly streamlined product formulation
- Tolerance testing of purification processes in Study #19 yields valuable direction for larger validation study
- Study #20 to commence in Q4 to validate purification processes in longer, larger study with more complete testing
- Study #21 to commence in staggered start after Study #20 to test highly purified biopharma candidate and synthetic bioactive (API)



Porcine Product Validation & Licensing



Biotech
Biotechnology
y

Molecules
Compounds
Complexes



Discovery Stage Licensing Candidate

- Study #2 to is docketed to commence after poultry licensing is closed
- Initially, studies are targeting gut health and gut-related maladies
- Weanlings are the primary study subjects
- Different methods of administration will be studied, as well





Bovine Applications & Licensing



Biotech
Biotechnology
Molecules
Compounds
Complexes



Discovery Stage Licensing Candidate

- Research resumes after poultry and swine licenses are executed
- Bovine mastitis remains primary target
- Oral administration unlikely
- May be reprioritized below canine res





Human Applications & Licensing



Biotech
Biotechnology
Molecules
Compounds
Complexes



Discovery Stage Licensing Candidate

- Positive preliminary testing provides direction for future research
- Immune and inflammation primary targets
- Initially, sepsis and arthritis R&D focus
- May be reprioritized based on strategy changes





Human Applications Development



AgTech Algal Biomass
Extracts
Agricultural Technology Dry Mixes



Topical Skin Health Candidate

- Product development launched mid 2020
- Initial analysis indicates potential benefits
- Algal paste product candidate passes USDA stain and irritant test (SIT)
- Algal paste passes USP 51 Preservative Efficacy Test (PET)





Human Applications Development



AgTech Algal Biomass
Extracts
Agricultural Technology Dry Mixes



Topical Skin Health Candidate

- Clinical efficacy testing is very promising
- Reduced fine wrinkles by 51.98%
- Reduced skin pore size by 38.76%
- Additional test planned over the next several weeks





Human Applications Development



AgTech Algal Biomass
Extracts
Agricultural Technology Dry Mixes



Topical Skin Health Candidate

- Clinical efficacy testing is very promising
- Reduced fine wrinkles by 51.98%
- Reduced skin pore size by 38.76%
- Additional test planned over the next several weeks





Human Applications Development



AgTech Algal Biomass
Extracts
Agricultural Technology Dry Mixes



Topical Skin Health Candidate

- Algal extract formulated as topical serum
- Proprietary facial mist formulated and tested in focus group
- All products share the same compliance pathway
- Low-volume/high-margin products to drive early revenues





Algal Biomass Production



AgTech Algal Biomass
Extracts
Agricultural Technology Dry Mixes



Building Production Volume


- Phase 1 contract with Alimenta Algae, Peru
- Phase 1 contract extension for buildout now in negotiations
- Vidalgas groundbreaking delayed due to unusually wet weather
- Vidalgas purchased laboratory equipment for on-site scaling and seeding of inoculum



Algal Biomass Production



ZIVO plans a global algae production network and derive revenues from selling biomass and joint ventures that market formulated products featuring ZIVO natural biomass products





Florida Mid-Scale Process Laboratory

- Supplies growers with inoculum, technical and scientific support
 - Mid-scale process optimization for photobioreactors and pond systems
 - New photobioreactors in startup mode
 - Houses ZIVO algal cultures and various lots of dried algal biomass
 - QA/QC benchmarks developed and promulgated throughout supply chain
-



COVID -19 Related Delays



Biotech
Biotechnology

AgTech
Agricultural Technology



Virtualized Research & Development

- R&D spread across multiple universities, labs, contract research organizations
- Personnel shortages, schedule backups affecting ZIVO research network
- Supply chain interruptions, price inflation
- Company actively developing workarounds and contingency plans



2021 Annual Shareholder Meeting

Q&A



2021 Annual Shareholder Meeting

THANK YOU

October 12, 2021
Detroit, Michigan



